Trials / Terminated
TerminatedNCT02657369
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to evaluate objective response rate (\[ORR\]: complete response \[CR\] and partial response \[PR\]) by investigator review in participants with anaplastic thyroid cancer (ATC) treated with lenvatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib 24 mg |
Timeline
- Start date
- 2016-07-07
- Primary completion
- 2018-09-26
- Completion
- 2018-09-26
- First posted
- 2016-01-15
- Last updated
- 2019-10-15
- Results posted
- 2019-10-15
Locations
30 sites across 5 countries: United States, Australia, France, Italy, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02657369. Inclusion in this directory is not an endorsement.